bazedoxifene BZA-20
Phase 3Completed 0 watching 0 views this week๐ Rising
76
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Postmenopause
Conditions
Postmenopause, Osteoporosis
Trial Timeline
May 1, 2006 โ Sep 1, 2007
NCT ID
NCT00384072About bazedoxifene BZA-20
bazedoxifene BZA-20 is a phase 3 stage product being developed by Pfizer for Postmenopause. The current trial status is completed. This product is registered under clinical trial identifier NCT00384072. Target conditions include Postmenopause, Osteoporosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00384072 | Phase 3 | Completed |
Competing Products
16 competing products in Postmenopause